close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

1.430 -0.010 (-0.69%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Allogene Therapeutics, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Recap: Allogene Therapeutics Q1 Earnings ↗
 
Via Benzinga
News headline image
Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Where Allogene Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
10 Analysts Have This to Say About Allogene Therapeutics ↗
 
Via Benzinga
News headline image
Allogene Therapeutics's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
What 10 Analyst Ratings Have To Say About Allogene Therapeutics ↗
 
Via Benzinga
News headline image
7 Short-Squeeze Stocks That Could Make You Rich ↗
Although moving against the grain presents its own distinct set of risks, these short-squeeze stocks may profit the contrarian. 
Via InvestorPlace
News headline image
Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
7 Short-Squeeze Stocks That Could Explode in April ↗
Although these short-squeeze stocks attracted bearish attention justifiably, contrarian sentiment may see them jump higher. 
Via InvestorPlace
News headline image
Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
Report Highlights Company’s Mission to Democratize Patient Access to CAR T While Maintaining Focus on Employee Engagement, Sustainability and Corporate Governance 
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Short Interest Update - Monday, March 27 ↗
Although equities broadly are starting the new week higher, the most heavily shorted stocks are trading lower today. 
Via Talk Markets
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023 ↗
 
Via Benzinga
News headline image
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds? 
Via News Direct
Topics Economy
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
By David Willey, Benzinga 
Via TheNewswire.com
Topics Economy
News headline image
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds? ↗
Cryoport Inc. (NASDAQ: CYRX) provides the life sciences industry with comprehensive supply chain solutions to support vital therapeutics. 
Via Benzinga
News headline image
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Short Squeezes Have Returned in 2023 -- Here's Your Playbook ↗
We haven't seen moves like these in a couple of years, so here's what investors should know. 
Via The Motley Fool
News headline image
Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Allogene Therapeutics Shares Are Seeing Blue Skies Today ↗
Allogene Therapeutics Inc (NASDAQ: ALLO) shares are trading higher by 13.1% to $7.76 Tuesday morning after the company announced data from its Phase 1 UNIVERSAL trial of ALLO-715 has been published in... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today